• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
LI Tonghui, GUO Hao, LU Tao, WANG Yue, LU Shuai, TANG Weifang. Advances in the research of FLT3 inhibitors for acute myeloid leukemia[J]. Journal of China Pharmaceutical University, 2015, 46(2): 153-161. DOI: 10.11665/j.issn.1000-5048.20150203
Citation: LI Tonghui, GUO Hao, LU Tao, WANG Yue, LU Shuai, TANG Weifang. Advances in the research of FLT3 inhibitors for acute myeloid leukemia[J]. Journal of China Pharmaceutical University, 2015, 46(2): 153-161. DOI: 10.11665/j.issn.1000-5048.20150203
shu

Advances in the research of FLT3 inhibitors for acute myeloid leukemia

More Information
    Graphical Abstract
    • Abstract
  • Acute myeloid leukemia(AML)is one of the most common acute leukemias in adults. Those patients with FLT3 mutations have a particularly poor prognosis. Recently, the emergence of a variety of targeted inhibitors has shown the capability of suppressing FLT3 signaling in vivo, which provided a new way to treat AML. In this paper, we reviewed those inhibitors based on their structures, which include indolone-related inhibitors, indolocarbazo-related inhibitors, benzimidazole/benzopyrazole-related inhibitors, quinoline/quinoxaline/quinazoline-related inhibitors, tricyclic inhibitors, pyrimidine-related inhibitors and others.
    • FullText(HTML)
    • References (69)
  • [1]
    Howlader N, Noone AM, Krapcho M, et al. SEER stat fact sheets:acute myeloid leukemia[EB/OL].2013.http://seer.cancer.gov/csr/1975_2010/.
    [2]
    Lowenberg B,Downing JR,Burnett A.Acute myeloid leukemia[J].N Engl J Med,1999,341(14):1051-1062.
    [3]
    Kelly LM, Gilliland DG. Genetics of myeloid leukemias[J].Annu Rev Genomics Hum Genet,2002,3(1):179-198.
    [4]
    Ley T,Miller C,Ding L,et al.Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia[J].N Engl J Med,2013,368(22):2059-2074.
    [5]
    Gilliland DG,Griffin JD.The roles of FLT3 in hematopoiesis and leukemia[J].Blood,2002,100(5):1532-1542.
    [6]
    Geer PV,Hunter T,Lindberg RA.Receptor protein-tyrosine kinases and their signal transduction pathways[J].Ann Rev Cell Biol,1994,10(1):251-337.
    [7]
    Carow CE,Kim E,Hawkins AL,et al.Localization of the human stem cell tyrosine kinase-1 gene(FLT3)to 13q12→ q13[J].Cytogenet Genome Res,1995,70(3/4):255-257.
    [8]
    Lyman S,James L,Johnson L,et al.Cloning of the human homologue of the murine FLT3 ligand:a growth factor for early hematopoietic progenitor cells[J].Blood,1994,83(10): 2795-2801.
    [9]
    Small D,Levenstein M,Kim E,et al.STK-1,the human homolog of Flk-2/Flt-3,is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells[J]. Proc Natl Acad Sci U S A, 1994,91(2): 459-463.
    [10]
    Hay N,Sonenberg N.Upstream and downstream of mTOR[J]. Genes Dev,2004,18(16): 1926-1945.
    [11]
    Roux PP,Blenis J.ERK and p38 MAPK-activated protein kinases:a family of protein kinases with diverse biological functions[J].Microbiol Mol Biol Rev,2004,68(2):320-344.
    [12]
    Manning BD,Cantley LC.AKT/PKB signaling:navigating downstream[J].Cell,2007,129(7):1261-1274.
    [13]
    Bar-Natan M,Nelson EA,Xiang M,et al.STAT signaling in the pathogenesis and treatment of myeloid malignancies[J].JAK-STAT,2012,1(2):55-64.
    [14]
    Carow C,Levenstein M,Kaufmann S,et al.Expression of the hematopoietic growth factor receptor FLT3 (STK-1/FLK2)in human leukemias[J].Blood,1996,87(3):1089-1096.
    [15]
    Rosnet O,Bühring HJ,Marchetto S,et al.Human FLT3/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells[J].Leukemia,1996,10(2):238-248.
    [16]
    Kiyoi H,Towatari M,Yokota S,et al.Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product[J].Leukemia,1998,12(9):1333-1337.
    [17]
    Nakao M,Yokota S,Iwai T,et al.Internal tandem duplication of the FLT3 gene found in acute myeloid leukemia[J].Leukemia,1996,10(12):1911-1918.
    [18]
    Kayser S,Schlenk RF,Londono MC,et al.Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome[J].Blood,2009,114(12):2386-2392.
    [19]
    Marcucci G,Haferlach T,Döhner H.Molecular genetics of adult acute myeloid leukemia:prognostic and therapeutic implications[J].Clin Oncol,2011, 29(5):475-486.
    [20]
    Schnittger S,Bacher U,Haferlach C,et al.Diversity of the juxtamembrane and TKD1 mutations(exons 13-15)in the FLT3 gene with regards to mutant load,sequence,length,localization,and correlation with biological data[J].Genes Chromosomes Cancer,2012,51(10):910-924.
    [21]
    Levis M,Small D.FLT3:ITDoes matter in leukemia[J].Leukemia,2003,17(9):1738-1752.
    [22]
    Stirewalt DL,Kopecky KJ,Meshinchi S,et al.Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia[J].Blood,2006,107(9):3724-3726.
    [23]
    Thiede C,Steudel C,Mohr B,et al.Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia:association with FAB subtypes and identification of subgroups with poor prognosis[J].Blood,2002,99(12):4326-4335.
    [24]
    Pratz KW,Sato T,Murphy KM,et al.FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML[J].Blood,2010,115(7):1425-1432.
    [25]
    Abu‐Duhier FM,Goodeve AC,Wilson GA,et al.Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia[J].Br J Haematol,2001,113(4):983-988.
    [26]
    Yamamoto Y,Kiyoi H,Nakano Y,et al.Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies[J].Blood,2001,97(8):2434-2439.
    [27]
    Moreno I,Martín G,Bolufer P,et al.Incidence and prognostic value of FLT3 internal tandem duplication and D835 mutations in acute myeloid leukemia[J].Haematologica,2003,88(1):19-24.
    [28]
    Gale RE,Green C,Allen C,et al.The impact of FLT3 internal tandem duplication mutant level,number,size,and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia[J].Blood,2008,111(5):2776-2784.
    [29]
    Schnittger S,Bacher U,Kern W,et al.Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia[J].Leuke-mia,2011, 25(8):1297-1304.
    [30]
    Kancha RK,Grundler R,Peschel C,et al.Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations[J].Exp Hematol,2007,35(10):1522-1526.
    [31]
    Fiedler W,Kayser S,Kebenko M,et al.A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia(AML)or not amenable to conventional therapy for the disease[J].Blood,2005,105(3):986-993.
    [32]
    Motzer R.,Hutson T,Tomczak P,et al.Sunitinib versus interferon alfa in metastatic renal-cellcarcinoma[J].N Engl J Med,2007,356(2):115-124.
    [33]
    Demetri GD,van Oosterom AT,Garrett CR,et al.Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib:a randomised controlled trial[J].Lancet,2006,368(9544):1329-1338.
    [34]
    Stone RM,DeAngelo DJ,Klimek V,et al.Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor,PKC412 [J].Blood,2005,105(1):54-60.
    [35]
    Fischer T,Stone RM,DeAngelo DJ,et al.Phase IIB trial of oral Midostaurin(PKC412),the FMS-like tyrosine kinase 3 receptor(FLT3)and multi-targeted kinase inhibitor,in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3[J].J Clin Oncol,2010,28(28):4339-4345.
    [36]
    Stone R,Fischer T,Paquette R,et al.Phase Ib study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adultpatients with acute myeloid leukemia[J].Leukemia,2012,26(9):2061-2068.
    [37]
    Smith BD,Levis M,Beran M,et al.Single-agent CEP-701,a novel FLT3 inhibitor,shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia[J].Blood,2004,103(10):3669-3676.
    [38]
    Knapper S,Burnett A,Littlewood T,et al.A phase 2 trial of the FLT3 inhibitor lestaurtinib(CEP701)as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy[J].Blood,2006,108(10):3262-3270.
    [39]
    Levis M,Ravandi F,Wang ES,et al.Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse[J].Blood,2011,117(12):3294-3301.
    [40]
    Hayley Ma,Bao Nguyen,Li Li,et al.TTT-3002 is a novel FLT3 tyrosine kinase inhibitor with activity against FLT3-associated leukemias in vitro and in vivo[J].Blood,2015,123(10):1525-1534.
    [41]
    Howard S,Berdini V,Boulstridge JA,et al.Fragment-based discovery of the pyrazol-4-yl urea(AT9283),a multitargeted kinase inhibitor with potent aurora kinase activity[J].J Med Chem,2008,52(2):379-388.
    [42]
    Pratz KW,Cortes J,Roboz GJ,et al.A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response[J].Blood,2009,113(17):3938-3946.
    [43]
    Kelly LM,YuJ C,Boulton CL,et al.CT53518,a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia(AML)[J].Cancer Cell,2002,1(5):421-432.
    [44]
    Pandey A,Volkots D L,Seroogy JM,et al.Identification of orally active,potent,and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family[J].J Med Chem,2002,45(17):3772-3793.
    [45]
    DeAngelo DJ,Stone RM,Heaney ML,et al.Phase 1 clinical results with tandutinib(MLN518),a novel FLT3 antagonist,in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome:safety,pharmacokinetics,and pharmacodynamics[J].Blood,2006,108(12):3674-3681.
    [46]
    Smith CC,Lasater E,Mccreery M,et al.Crenolanib(CP-868596)is a potent and selective type I FLT3 inhibitor that retains activity against AC220 resistancecausing FLT3 kinase domain mutants[J].Blood(ASH Annual Meeting Abstracts),2012,120(21):141.
    [47]
    Galanis A,Rajkhowa T,Muralidhara C,et al.Crenolanib:a next generation FLT3 inhibitor[J].Cancer Res,2012,72(8):3660.
    [48]
    Zimmerman E,Turner D,Buaboonnam J,et al.Crenolanib is active against models of drug-resistant FLT3-ITD positive acute myeloid leukemia[J].Blood,2013,122(22):3607-3615.
    [49]
    Smith DC,Smith MR,Sweeney C,et al.Cabozantinib in patients with advanced prostate cancer:results of a phase II randomized discontinuation trial[J].J Clin Oncol,2013,31(4):412-419.
    [50]
    Kurzrock R,Sherman SI,Ball DW,et al.Activity of XL184 (Cabozantinib),an oral tyrosine kinase inhibitor,in patients with medullary thyroid cancer[J].J Clin Oncol,2011,29(19):2660-2666.
    [51]
    Renhowe PA,Pecchi S,Shafer CM,et al.Design,structure-activity relationships and in vivo characterization of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones:a novel class of receptor tyrosine kinase inhibitors[J].J Med Chem,2008,52(2):278-292.
    [52]
    Wang X,Kay A,Anak O,et al.Population pharmacokinetic/pharmacodynamic modeling to assist dosing schedule selection for dovitinib[J].J Clin Pharmacol J New Drugs,2013,53(1):14-20.
    [53]
    Chung TW,Chen CH,Lin CC,et al.Exploring a sulfone linker utilizing trimethyl aluminum as a cleavage reagent:solid-phase synthesis of sulfonamides and ureas[J].Mol Divers,2012,16(3):463-476.
    [54]
    Albers C,Leischner H,Verbeek M,et al.The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+AML but retains in vitro sensitivity to PKC412 and Sunitinib[J].Leukemia,2013,27(6):1416-1418.
    [55]
    Cortes J E,Kantarjian H,Foran J M,et al.Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status[J].J Clin Oncol,2013,31(29):3681-3687.
    [56]
    Cortes JE,Perl AE,Dombret H,et al.Final results of a phase 2 open-label,monotherapy efficacy and safety study of quizartinib(AC220)in patient 60 years of age with FLT3 ITD positive or negative relapsed/refractory acute myeloid leukemia[C]//ASH Annual Meeting Abstracts,2012,120(21):48.
    [57]
    Levis MJ,Perl AE,Dombret H,et al.Final results of a phase 2 open-label,monotherapy efficacy and safety study of quizartinib(AC220)in patients with FLT3-ITD positive or negative relapsed/refractory acute myeloid leukemia after second-line chemotherapy or hematopoietic stem cell transplantation[C]//ASH Annual Meeting Abstracts,2012,120(21):673.
    [58]
    Hart S,Goh KC,Novotny-Diermayr V,et al.SB1518,a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies[J].Leukemia,2011,25(11):1751-1759.
    [59]
    Poulsen A,William A,Blanchard S,et al.Structure-based design of oxygen-linked macrocyclic kinase inhibitors:discovery of SB1518 and SB1578,potent inhibitors of Janus kinase 2 (JAK2)and Fms-like tyrosine kinase-3 (FLT3)[J].J Comput Aided Mol Des,2012,26(4):437-450.
    [60]
    Hart S, Goh KC, Novotny-Diermayr V, et al. Pacritinib(SB1518),a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia[J].Blood Cancer J,2011,1(11):e44.
    [61]
    Fletcher GC,Brokx RD,Denny TA,et al.ENMD-2076 is an orally active kinase inhibitor with antiangiogenic and antiproliferative mechanisms of action[J].Mol Cancer Ther,2011,10(1):126-137.
    [62]
    Wilhelm SM,Carter C,Tang LY,et al.BAY43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis[J].Cancer Res,2004,64(19):7099-7109.
    [63]
    Escudier B,Eisen T,Stadler WM,et al.Sorafenib in advanced clear-cell renal-cell carcinoma[J].N Engl J Med,2007,356(2):125-134.
    [64]
    Llovet JM,Ricci S,Mazzaferro V,et al.Sorafenib in advanced hepatocellular carcinoma[J].N Engl J Med,2008,359(4):378-390.
    [65]
    Zhang W,Konopleva M,Shi YX,et al.Mutant FLT3:a direct target of sorafenib in acute myelogenous leukemia[J].Natl Cancer Inst,2008,100(3):184-198.
    [66]
    Pratz K,Cho E,Levis M,et al.A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias[J].Leukemia,2010,24(8):1437-1444.
    [67]
    Metzelder S,Schroeder T,Finck A,et al.High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses[J].Leukemia,2012,26(11):2353-2359.
    [68]
    Jain P,Kantarjian H,Cortes J.Chronic myeloid leukemia:overview of new agents and comparative analysis[J].Curr Treat Options Oncol,2013,14(2):127-143.
    [69]
    Lee HK, Kim HW, Lee IY, et al. G-749, a novel FLT3 kinase inhibitor,can overcome drug resistance for the treatment of acute myeloid leukemia[J].Blood,2014,123(14):2209-2219.
    • Related Articles

  • Related Articles

    [1]LI Linzhen, WEI Xi, LIU Lu, LI Yongjun, LIANG Jingyu. Chemical constituents from the stems of Clerodendrum trichotomum Thunb.[J]. Journal of China Pharmaceutical University, 2019, 50(5): 544-548. DOI: 10.11665/j.issn.1000-5048.20190506
    [2]LIN Qinghua, XU Jian, FENG Feng. Chemical constituents from the stems of Picrasma quassioides Bennet[J]. Journal of China Pharmaceutical University, 2017, 48(6): 675-679. DOI: 10.11665/j.issn.1000-5048.20170607
    [3]XU Yunhui, JIANG Xueyang, XU Jian, JIANG Renwang, ZHANG Jie, XIE Zijian, FENG Feng. Chemical constituents from Callicarpa kwangtungensis Chun[J]. Journal of China Pharmaceutical University, 2016, 47(3): 299-302. DOI: 10.11665/j.issn.1000-5048.20160309
    [4]MA Lin, ZHANG Rongfei, YU Shule, WU Zhengfeng, ZHAO Shouxun, Wang Lei, YE Wencai, ZHANG Jian, YIN Zhiqi. Chemical constituents of Fructus Gleditsiae Abnormalis[J]. Journal of China Pharmaceutical University, 2015, 46(2): 188-193. DOI: 10.11665/j.issn.1000-5048.20150209
    [5]LI Linzhen, WANG Menghua, SUN Jianbo, LIANG Jingyu. Chemical constituents from Aletris spicata[J]. Journal of China Pharmaceutical University, 2014, 45(2): 175-177. DOI: 10.11665/j.issn.1000-5048.20140208
    [6]CHANG Bo, XIAO Linjing, ZHANG Jian, ZHAO Shouxun, YE Wencai, YIN Zhiqi. Chemical constituents from Abies ernestii var.salouenensis[J]. Journal of China Pharmaceutical University, 2014, 45(1): 43-47. DOI: 10.11665/j.issn.1000-5048.20140107
    [7]LI Jiu-hui, CHEN Guang-ying, HAN Chang-ri, MO Zheng-rong, SONG Xiao-ping. Chemical constituents from the stems of Vatica mangachpoi Blanco[J]. Journal of China Pharmaceutical University, 2012, 43(1): 25-27.
    [8]SUN Jing, YIN Zhi-qi, ZHANG Qing-wen, YE Wen-cai, WANG Yi-ta, ZHAO Shou-xun. Chemical constituents from ethyl acetate extract of Ganoderma lucidum[J]. Journal of China Pharmaceutical University, 2011, 42(3): 220-222.
    [9]Chemical constituents from n-butanol extract of the stems of Lonicera japonica[J]. Journal of China Pharmaceutical University, 2010, 41(4): 333-336.
    [10]Chemical constituents from Senecio nemorensis.[J]. Journal of China Pharmaceutical University, 2010, 41(1): 26-28.

Catalog

    Get Citation
    PDF
    XML
    Article views (1239) PDF downloads (5246) Cited by()
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Copyright © Journal of China Pharmaceutical University苏ICP备12050101号-2

    Address：24 Tongjia Lane, Nanjing City, Jiangsu Province （210009）Tel: 025-83271566E-mail: xuebao@cpu.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    Total visits：292644

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return